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A B S T R A C T
Background: The wide morphological variety of coarctation of the aorta (CoA) and some complications 
resulting from the implantation of conventional stents has made the utilization of covered stents (CS) 
desirable. We describe our experience with the use of CS to treat CoA in children and adults.
Methods: The records of patients that received CS were retrospectively reviewed. The procedures were 
performed according to the established technique. Use of CS as primary treatment were assessed, as well 
as those deployed due to complications resulting from the initial procedure. 
Results: Between 2007 and 2014, CS were used in 14 patients, 9 (64.3%) of whom were males. The mean 
age was 19.5 ± 10.5 years, and the mean weight 61.7 ± 25.5 kg. Bicuspid aortic valve was present in 74% of 
cases, and two patients had patent ductus arteriosus. Subatretic aortic coarctations were found in five 
patients. Eleven patients had systemic arterial hypertension, and 73% had normalized blood pressure levels 
after stent dilation. Implantation was possible in all cases. Primary implants were performed in ten (71.4%) 
patients with native coarctation and in four patients as a second device to correct problems originating 
from previous procedures. The mean time of follow-up was 51.7 ± 29.8 months. Three minor complications 
were related to procedures, and there were no deaths. 
Conclusions: The use of CS was safe and effective in this small case series. Further studies focusing on the 
long-term evolution and the possibility of CS redilation are needed to support its use in children.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Uso de stents recobertos no tratamento da coarctação da aorta
R E S U M O
Introdução: A ampla variedade morfológica das coarctações da aorta (CoA) e algumas complicações derivadas 
do implante de stents convencionais tornam desejáveis a utilização de stents recobertos (SR). Descrevemos a 
experiência com o uso de SR para tratar CoA em crianças e adultos. 
Métodos: Foram revisados, retrospectivamente, os registros dos pacientes nos quais foram utilizados os SR. 
Os procedimentos foram realizados segundo a técnica consagrada. Foram estudados casos em que os SR 
foram utilizados como primeiro tratamento e também aqueles realizados em complicações derivadas do 
procedimento inicial. 
Resultados: Entre 2007 e 2014, foram utilizados SR em 14 pacientes, sendo 9 (64,3%) do sexo masculino. 
A média de idades foi 19,5 ± 10,5 anos, e a média dos pesos, 61,7 ± 25,5 kg. Valva aórtica bicúspide estava 
presente em 74% dos casos, e dois apresentaram persistência do canal arterial. Coarctações subatréticas 
foram encontradas em cinco pacientes. Onze pacientes apresentaram hipertensão arterial sistêmica, e 
73% normalizaram as cifras tensionais após a dilatação com stents. O implante foi possível em todos os 
casos. Foram realizados implantes primários em dez (71,4%) pacientes portadores de coarctações nativas 
e em quatro como segundo dispositivo, para corrigir problemas derivados de procedimentos anteriores. O 
tempo médio de seguimento foi de 51,7 ± 29,8 meses. Três complicações menores estiveram relacionadas 
aos procedimentos, e não houve registro de óbito. 
Conclusões: O uso de SR foi seguro e eficaz na nossa pequena série de casos. Mais estudos, enfocando a evolução 
de longo prazo e a possibilidade de redilatação dos SR, são necessários para corroborar seu uso em crianças.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
The treatment of coarctation of the aorta (CoA) has been evolving 
over time, and balloon angioplasty has become a less invasive alter-
native to surgery.1
Recently, the use of balloon-expandable stents has become the 
treatment of choice for CoA in adolescents and adults.2,3 The wide 
morphological variety of  CoA and some complications resulting 
from the utilization of conventional stents has made the use of cove-
red stents (CS) desirable.4,5
In this study, the authors describe their experience with the CS to 
treat CoA in children and adults. They also discuss their indications 
for use in native lesions and their applications in addressing some 
complications of this procedure.
Methods
The records of all patients referred for percutaneous treatment of 
CoA in whom CS were used were retrospectively analyzed. All pro-
cedures were conducted under general anesthesia and orotracheal 
intubation, after a minimum fasting period of 8 hours.
Heparin was administrated at doses of 100 IU/kg in children and 
5,000 to 10,000 IU in adults, after obtaining the arterial access. Anti-
biotic prophylaxis with cefazolin (50 mg/kg in children or 2 g in 
adults) was routinely administered. Patients underwent left heart 
catheterization by femoral artery access.
Lesions were retrogradely crossed using a pre-shaped catheter 
for the right coronary (JR), into which a straight-tip hydrophilic gui-
dewire was advanced. Once the ascending aorta was reached, pres-
sures were recorded above and below the lesion, and the gradient 
was obtained.
Using a calibrated pigtail catheter, a panoramic aortography was 
performed in the left anterior oblique projection at 30°, and a 
descending aortography was performed in the following projec-
tions: left anterior oblique at 60°, right anterior oblique, and left late-
ral. In some cases, a small caudal angulation was added for better 
visualization of the obstruction site (Fig. 1).
After the angiography, the transverse aorta diameters between 
the carotid arteries, the isthmus region at the origin of the left sub-
clavian artery, the obstruction site, and the descending aorta below 
the lesion were measured. The length was measured from the base 
of the left subclavian artery to the descending aorta region, in order 
to completely encompass the coarcted area.
After lesion documentation, an exchange guidewire, rigid or 
super-rigid, was positioned in the left subclavian artery or ascen-
ding aorta above the valve. Over it, a long sheath with a gauge of 
at least 3 F greater than the nominal balloon catheter caliber was 
introduced and advanced beyond the obstructed area.
Through the sheath, the chosen CS was advanced, manually 
mounted on a balloon with a diameter of 1 to 2 mm larger than 
that of the isthmic region or the transverse aorta, between the 
carotid arteries, measuring 1 to 2 cm longer than the stent leng-
th. The authors chose stents whose length were close to that ob-
tained by the angiographic measurement of the distance from 
the lower border of the transverse aorta until the descending 
aorta was reached, in order to place the affected region in its 
central portion.
The balloon/stent set was advanced over the guidewire and 
positioned with the aid of contrast injections through the lateral 
access of the long sheath. Then, the balloon was inflated by ma-
nual inflators using pressures lower than the rated burst pressu-
re. Correct apposition of the CS to the aortic wall was checked 
and the balloon was completely deflated and removed through 
the interior of the sheath, carefully so as not to displace the ex-
change guidewire. The pigtail catheter was reintroduced over 
the guide and the record of the pressures above and below the 
CS was performed. Control angiograms were performed using 
the same previous projections.
New dilations, with balloons of greater diameter than the ori-
ginal one, were performed when stent expansion was considered 
insufficient or adequate apposition of the upper end of the device 
to the aortic walls was not achieved. At the end of the procedure, 
hemostasis was performed by manual compression or with the 
use of auxiliary hemostatic systems, when available.
Patients were referred to the intensive care unit, where they 
remained under observation until the following day, undergoing 
electrocardiographic and blood pressure monitoring. They were 
discharged after undergoing transthoracic echocardiograms.
Follow-up with transthoracic echocardiography was conduc-
ted after 1, 3, and 6 months. After 6 months, thoracic aorta CT 
angiographies were performed to verify the adequate CS apposi-
tion to the aortic wall, as well as to rule out the presence of 
aneurysms or dissections. A stress test was also requested to 
assess the blood pressure curve during exercise.
Types of stents used 
The Advanta V12 CS (Atrium Medical – Hudson, USA) are made 
of a laser-cut stainless steel structure with a double cover of ex-
panded polytetrafluoroethylene (e-PTFE), placed outside and insi-
de of the stent metal structure. The stents have an open-cell 
geometry and are mounted on the balloon by the manufacturer. 
They are marketed at lengths of 29, 41, and 61 mm, mounted on 
balloons with 12, 14, and 16 mm of diameter. They can be dilated to 
a maximum diameter of 22 mm and their shortening rate is appro-
ximately 25%.6
The Cheatham Platinum CS (Numed – Hopkinton, USA) are 
made of a platinum-iridium alloy wire, shaped and welded into a 
cylindrical form. They are covered only on their external surface 
by an e-PTFE membrane. The devices have a circumference con-
sisting of eight diamond-shaped cells, called "8 zigs". The unex-
panded cell measures 11 mm. Other cell cylinders can be 
longitudinally welded to the initial one, increasing the stent len-
gth. The minimum recommended diameter for dilat ion is 
8 mm and the maximum, 24 mm, with a nominal shortening rate 
of 20%. From December 2002 onwards, the welds were reinforced 
with gold.7
Figure 1. Descending aortography in the left projection. In (A), there is a gradual reduc-
tion in the aorta diameter, from the origin of the left subclavian artery, ending in the 
focal coarcted area at the end of the aortic isthmus (tubular hypoplasia). Note the 
post-stenotic dilation of the descending aorta. In (B), severe segmental coarctation is 
observed, encompassing the entire aortic isthmus. The reduced caliber of the descend-
ing aorta can be observed, which does not present the usual post-stenotic dilation.
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Results
From September 2007 to December 2014, CS were used in 14 pa-
tients, of whom nine were males (64.3%), with a mean age of 19.5 ± 
10.5 years (range 4 to 40 years), and mean weight of 61.7 ± 25.5 kg 
(ranging from 17 to 95 kg).
Ten patients (71.4%) had associated bicuspid aortic valves. Only 
two had aortic regurgitation − mild (1/4 +) in one case and moderate 
(2/4 +) in another one, which also had an ascending aortic aneurysm 
(Case 6). Two patients had patent ductus arteriosus (PDA; Cases 2 
and 9; Fig. 2).
In all patients, the  CoA  was located in the usual region, at the 
end of the aortic isthmus. Only one patient had segmental hypopla-
sia after the left subclavian artery origin. The lesion was focal in the 
other cases (Table 1).
The mean diameter in the  CoA region was 6.2 ± 4.7 mm (range 1.7 
to 15 mm). The lesion was considered subatretic (less than 3 mm in 
diameter) in five cases (Fig. 3).
Before the procedure, 11 patients (78.5%) had hypertension and 
were receiving different treatments prescribed by their attending 
physicians. After the stent implantation, eight patients normalized 
their blood pressure levels at rest and on exertion, and anti-hyper-
tensive medication cessation was recommended.
Stent deployment was possible in all cases. Primary implanta-
tions were carried out in ten (71.4%) patients with native coarcta-
tion. No lesion pre-dilation was necessary in any case. In four cases 
(Cases 11-14), a second device was implanted to correct problems 
arising from previous procedures.
Eighteen stents were deployed in 14 patients. The devices used 
are detailed in Table 2.
One patient (Case 4) required hyperexpansion of the stent with a 
second balloon with a diameter 2 mm greater than the previous one, 
to attain the correct apposition of the device to the aortic wall in the 
same procedure.
Four patients had clinical and echocardiographic signs of reco-
arctation. In the first three cases (Cases 3, 10, and 14) Advanta V12 
CS were implanted. Angiographies performed in subsequent cardiac 
catheterizations showed that in two patients (Cases 3 and 10), both 
devices showed good apposition to the aortic wall, but disclosed in-
timal proliferation inside and were redilated with balloon, obtaining 
satisfactory results (Fig. 4).
Figure 2. Descending aortography in the left projection shows focal coarctation at the 
end of aortic isthmus and additionally, the presence of type A patent ductus arterio-
sus, resulting in opacification of the pulmonary trunk.
Figure 3. Aortography in caudal left anterior oblique projection, showing a very cons-
tricted coarctation, considered to be subatretic.
Table 1
Demographic data.
n ID Age (years) Weight (kg) BAV Associated defect
1 JNV 16 70 Yes No
2 KTG 25 86 Yes PDA
3 AVRS 6 24 Yes No
4 BVCA 4 17 Yes No
5 SGA 40 86 Yes No
6 JSS 22 50 Yes, with 2/4+ AR Ascending aorta 
aneurysm 
7 DRR 15 95 No No
8 GSP 32 85 No No
9 IVM 7 24 No PDA
10 EMP 18 60 Yes, with 1/4+ AR No
11 FNFA 34 50 Yes No
12 JVFS 17 75 Yes No
13 ITGS 17 79 No No
14 LCDNP 18 63 Yes No
ID: patient identification; BAV: bicuspid aortic valve; PDA: patent ductus arteriosus; AR: aortic regurgitation.
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In the third case (Case 14), the restenosis was caused by collapse 
of the upper border of an Advanta V12 16/61 CS, approximately 1 
year after the implantation performed in another hospital. Dilation 
was performed with the successful implantation of a second device, 
a Cheatham Platinum 8 ZIG-39 uncovered stent (Fig. 5).
The other case (Case 11) had recoarctation due to fracture of a 
Cheatham Platinum uncovered stent, discovered 7 years after im-
plantation. It was treated with dilation and implantation of a new 
Cheatham Platinum 8-ZIG 39 CS inside the first one.
Late aneurysm formation was observed in two patients. In one (Case 
12), there was a circumferential fracture in the first and final weld lines 
of a Cheatham Platinum 8-ZIG 34 uncovered stent. A posterior-superior 
strut fracture resulted in the formation of a small aneurysm. In the se-
cond patient (Case 13), the aneurysm was formed during the PALMA-
ZTM P308 uncovered stent implantation, whose borders were sharp. 
Treatment was successful in both cases, with implantation of the Chea-
tham Platinum 8 ZIG-45 CS and Cheatham Platinum 8-ZIG 39 CS, res-
pectively (Figs. 6 and 7).
The mean diameter of the balloons used in the procedure was 15.2 
± 3.1 mm (ranging from 12 to 20 mm). The mean systolic gradient 
through the obstructed area was reduced from 34.2 ± 16.0 mmHg 
(ranging from 10 to 64 mmHg) to 2.5 ± 4.6 mmHg (ranging from -6 to 
12 mmHg) after stent implantation. The mean diameter of the coarc-
ted segment increased from 6.2 ± 4.7 mm to 15.6 ± 2.8 mm. 
The mean time of follow-up was 51.7 ± 29.8 months (ranging 
from 2 to 88 months).
There were three complications related to procedures: an arterial 
stenosis at the site of a long sheath insertion, which required surgi-
cal repair (Case 4), one pseudoaneurysm treated by local compres-
sion (Case 6), and a case of right upper limb paresthesia due to 
hyperextension of the brachial plexus during the procedure (Case 
14). There were no deaths in this series.
Discussion
Balloon-expandable stents, covered by a layer of e-PTFE, have 
been used for the treatment of  CoA.8-12 The most commonly used are 
the Cheatham Platinum CS and the Advanta V12 LD. They are usually 
indicated in the following situations:13 patients older than 30 years; 
in cases of critical obstruction (diameter < 3 mm in the region of the 
CoA); when there is atresia of the aortic lumen; when the CoA is as-
sociated with PDA; when there are significant degenerative changes 
in the aortic wall; when it is necessary to perform aneurysm exclu-
sion or treat aorta dissections; in case of circumferential fracture 
with misalignment between the proximal and distal portions of a 
previously implanted stent; and in cases of partial or circumferential 
stent fracture, with strut protrusion against the aortic wall.
In the Platinum Cheatham CS, the e-PTFE membrane is sutured 
to the external area of the struts. This device must be mounted ma-
nually on the delivery balloon. Great care must be taken in order 
not to damage the outer membrane, which cannot be wetted and 
should be handled with dry and clean gloves. To avoid dislodging 
the cover, it is necessary to prevent excessive friction with the in-
Table 2
Balloons and stents used.




1 JNV BIB 18/50 CS CP 8 ZIG 45 26 -1
2 KTG BIB 18/40 CS CP 8-ZIG 39 58 -6
3 AVRS ATRIUM 12/50 and Z-MedTM 14/40 CS Advanta V12 12/41 47 2
4 BVCA Z-MedTM II 8/30 and Z-MedTM II 10/40 CS CP 8-ZIG 28 50 9
5 SGA BIB 16/50 CS CP 8-ZIG 45 30 1
6 JSS BIB 18/45 CS CP 8-ZIG 39 25 0
7 DRR BIB 12/40 CS CP 8-ZIG 45 26 1
8 GSP Z-MedTM II 14/40 CS CP 8-ZIG 45 37 3
9 IVM Power Flex Plus 12/40 CS CP 8-ZIG 28 64 5
10 EMP ATRIUM 12/41 and Z-MedTM II 16/40 CS Advanta V12 12/41 43 6
11 FNFA BIB 16/40 and Z-MedTM II 18/40 UNC CP 8-ZIG 39 and CS CP 8-ZIG 39 10 5
12 JVFS Power Flex Plus 12/40 and Z-MedTM II 18/40 UNC CP 8-ZIG 34 and CS CP 8-ZIG 45 15 1
13 ITGS Power Flex Plus 10/40, Power Flex Plus 12/40, Z-MedTM 14/40,  
and Z-MedTM II 18/40
UNC PALMAZTM P308  
and CS CP 8-ZIG 39 
22 12
14 LCDNP ATRIUM 16/60 and BIB 20/40 CS Advanta V12 16/61  
and UNC CP 8-ZIG 39 
66 -2
ID: patient identification; Grad: gradient across the aortic coarctation region; BIB: balloon-in-balloon; CS: covered stent; UNC: uncovered stent.
Figure 4. In (A), descending aortography immediately after the first implant (Case 3) 
showing the well-positioned stent with good flow. In (B), control aortography 5 years 
after implantation, showing luminal reduction by intimal proliferation along the enti-
re stent length.
Figure 5. In (A), detail of the Advanta covered stent disclosing collapse of his upper 
border, with partial lumen obstruction. In (B), recovery of aortic lumen after implan-
tation of a Cheatham Platinum uncovered stent.
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troducer sheath, which must have a caliber at least 3 F higher than 
the sheath recommended for the balloon use. This can be a limiting 
factor for the use of the Cheatham Platinum CS in children or small 
patients, with smaller-caliber arteries. When crossing the hemos-
tatic valve of the long sheath, one of the supplied protection cylin-
ders must be used together with the stent. If not available, they can 
be manufactured from a segment cut from a sheath of the same 
diameter used for the stent deployment. It would be desirable for 
the Cheatham Platinum CS to come pre-assembled by the manu-
facturer, which would reduce the time and increase the safety of 
the procedure, allowing its use in a larger number of small patients 
and even in children.
As they are non-permeable cylinders, due to the e-PTFE cover, 
the CS must show complete apposition into the aortic wall in the 
cephalic region of the isthmus and must not be positioned above 
the lower border of the transverse aorta. The presence of free spa-
ce between the stent borders and the aortic wall would create a 
sac where the high speed flow of the descending aorta could dis-
place the stent or even cause its collapse, resulting in obstruction, 
as reported in Case 14.14,15 The expansion of the lower border to 
the diameter of the dilated descending aorta does not seem ne-
cessary.
Redilation of the CS, although possible, is avoided by some au-
thors; therefore, its use should be carefully evaluated in children.16-18
Aortic dissection and rupture are important reasons for the 
emergency use of CS, which should be available for the rescue of 
the more severe cases.19
There is a small risk of spinal artery occlusion with the use of CS, 
although it originates well below the coarctation level. Additionally, 
it has not been a significant problem when using endoprosthesis for 
the treatment of major thoracic aortic aneurysms, occurring in only 
1 to 4% of cases.20
It is important to be careful to avoid unintentional exclusion of impor-
tant vessels, such as the subclavian and carotid arteries, when using CS.
Conclusions
The use of covered stents was safe and effective in this small 
case series. A reduction in the diameter of the long sheaths would 
be desirable. Further studies focusing on the long-term evolution 
and the possibility of redilation of covered stents, are needed to 
support their use elective, in children.
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Figure 6. In (A), detail of a Cheatham Platinum uncovered stent implanted 13 years ago. Note the circumferential fracture of the first and last row of "zigs". In (B), descending 
aortography in the right anterior artery, showing a dissection line with a small aneurysm in the region of the first row of fractured weld. In (C), control aortography after implan-
tation of a Cheatham Platinum covered stent with aneurysm exclusion.
Figure 7. In (A), control angiotomography after PalmazTM P308 uncovered stent implantation, showing the presence of a saccular aneurysm in its upper border. In (B), aneurysm 
exclusion 6 months after implantation of a Cheatham Platinum CS.
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